Alto Neuroscience
ANRO
23.52
-0.17
-0.72%
Alto Neuroscience
US · ANRO
#3301 by market cap
Listed 2024
23.52
-0.17
-0.72%
Live - 5344 symbols - heartbeat 276s ago
· 2026-10-08 09:17
Pre-market
23.24
-1.19%
After-hours
23.97
+1.92%
- Market cap
- 922.97M
- P/E (TTM)i
- -10.14
- P/Bi
- 4.21
- EPSi
- -2.19
- Div yieldi
- 0.00%
- 52W posi
- 57%
Reader sentiment
Are you bullish or bearish on ANRO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.5 percentage points.
Institutional ownership
- Held by institutions
- 86.59% -4.54pp
- Institutions
- 139 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund47.15%
Mutual Fund27.14%
VC/PE Fund11.01%
Individual/Insider2.51%
Public Company0.85%
Private Company0.15%
Insurance Company0.14%
Government Pension Fund0.10%
Other10.91%
Top holders as of 2026-06-30
Alpha Wave Global, LP
9.45% · 3.71M sh
Commodore Capital LP
6.94% · 2.72M sh
EcoR1 Capital, LLC
5.69% · 2.23M sh
BlackRock
5.40% · 2.12M sh
Perceptive Advisors LLC
4.10% · 1.61M sh
Vanguard Capital Management, LLC
4.08% · 1.60M sh
Adage Capital Management, L.P.
4.08% · 1.60M sh
Sirenia Capital Management LP
3.65% · 1.43M sh
Spruce Street Capital LP
3.45% · 1.35M sh
Vivo Capital, LLC
3.08% · 1.21M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 40 buys · 9 sells
| Name | Role | Stake |
|---|---|---|
| Amit Etkin | Founder, Chairman of the Board, CEO & President | 2.13% |
| Nicholas Smith | Chief Financial Officer | 0.20% |
| Po Chen | Director | 0.12% |
| Gwill York | Independent Director | 0.06% |
| Andrew Dreyfus | Independent Director | -- |
| Andrew Miller | Director | -- |
| Husseini Manji | Non-Employee Independent Director | -- |
| Raymond Sanchez | Director | -- |
| Michael Hanley | Chief Operating Officer | -- |
| Christopher Cox | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Nicholas Smith | Chief Financial Officer | Derivative Exercise and Retained | +55,000 | $2.32 |
| 2026-09-29 | Nicholas Smith | Chief Financial Officer | Derivative Exercise and Sale | -134,886 | $2.35–26.87 |
| 2026-09-28 | Nicholas Smith | Chief Financial Officer | Intent to Sell (Form 144) | -134,886 | $26.66 |
| 2026-05-26 | Andrew Miller | Director | Other Derivative Acquisition | +26,000 | $20.44 |
| 2026-05-13 | Amit Etkin | Founder, Chairman of the Board, CEO & President | Other Disposition | -400,000 | -- |
| 2026-05-11 | Gwill York | Independent Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-05-11 | Andrew Dreyfus | Independent Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-05-11 | Husseini Manji | Non-Employee Independent Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-05-11 | Raymond Sanchez | Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-05-11 | Christopher Cox | Independent Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-02-28 | Nicholas Smith | Chief Financial Officer | Sale to Issuer | -2,806 | $19.69 |
| 2026-02-28 | Amit Etkin | Founder, Chairman of the Board, CEO & President | Sale to Issuer | -6,227 | $19.69 |
| 2026-02-10 | Nicholas Smith | Chief Financial Officer | Other Derivative Acquisition | +200,000 | $16.71 |
| 2026-02-10 | Amit Etkin | Founder, Chairman of the Board, CEO & President | Other Derivative Acquisition | +306,000 | $16.71 |
| 2026-02-10 | Michael Hanley | Chief Operating Officer | Other Derivative Acquisition | +131,000 | $16.71 |
| 2026-02-10 | Adam Savitz | Chief Medical Officer | Other Derivative Acquisition | +124,000 | $16.71 |
| 2026-01-01 | Gwill York | Independent Director | Other Derivative Acquisition | +5,243 | $16.59 |
| 2026-01-01 | Husseini Manji | Non-Employee Independent Director | Other Derivative Acquisition | +4,228 | $16.59 |
| 2026-01-01 | Raymond Sanchez | Director | Other Derivative Acquisition | +3,806 | $16.59 |
| 2026-01-01 | Christopher Cox | Independent Director | Other Derivative Acquisition | +7,189 | $16.59 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:17:13 · For reference only, not investment advice and not tailored to your situation.